NCT06695585View on ClinicalTrials.gov

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions

Overactive BladderOveractive Bladder SyndromeUrinary UrgencyUrinary FrequencyUrge IncontinenceNeurogenic Bladder

Interventions

DRUG

Lidocaine 2% without vessel constrictor

different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared

Trial Locations (1)

40202

University of Louisville Division of Urogynecology and Reconstructive Pelvic Surgery, Louisville

All Listed Sponsors

lead

University of Louisville

OTHER

NCT06695585 - Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections | Biotech Hunter | Biotech Hunter